Published: June 2025 | Last updated: May 2026
Antibiotic-resistant sexually transmitted infections used to feel like a clinical-research problem, the kind that lived inside journals and slow-moving policy briefs. That window has closed. The CDC now classifies drug-resistant Neisseria gonorrhoeae as an urgent antibiotic-resistance threat, and the WHO's Gonococcal Antimicrobial Surveillance Programme has logged treatment failures on every populated continent. Mycoplasma genitalium has its own resistance pattern, and even syphilis carries macrolide-resistant strains in some regions.
That backdrop spawns a lot of confident misinformation: leftover Z-Pak advice, doxy-PEP overconfidence, and a habit of stopping antibiotics the moment symptoms ease. This piece walks through the five most stubborn myths and replaces each with current CDC, WHO, and NHS-aligned guidance, plus a clear note on where at-home rapid tests fit and where they do not.
The 2026 picture: where resistance actually stands
Resistance does not arrive as a single dramatic event. It creeps into the surveillance data: doses of an antibiotic stop clearing infections in 1% of cases, then 5%, then 20%, and clinicians are forced to retire the drug from frontline use. That pattern has already played out repeatedly with gonorrhea.
According to the CDC's drug-resistant gonorrhea page, Neisseria gonorrhoeae has developed resistance to nearly every antibiotic ever used to treat it: sulfonamides, penicillin, tetracycline, fluoroquinolones, and macrolides. Ceftriaxone is the last consistently effective drug for routine treatment, and several countries have already documented clinical failures with ceftriaxone-resistant strains.
Mycoplasma genitalium is the quieter story. The CDC STI Treatment Guidelines describe macrolide-resistance rates above 50% in many populations, with growing fluoroquinolone resistance on top of that, leaving very few reliable single-agent options.
Syphilis treatment has stayed simpler. Penicillin still works, but azithromycin-resistant Treponema pallidum strains have circulated for years and are common enough that the WHO and CDC advise against azithromycin as primary therapy. The WHO fact sheet on multi-drug-resistant gonorrhoea sits in this same urgent category for global health planners.
None of this means treatment has failed everywhere. It does mean the margin has narrowed, and that is the backdrop the next five myths each ignore.
Myth #1: "Resistance is rare and it won't happen to me"
The numbers say otherwise. According to the CDC's drug-resistant gonorrhea page, N. gonorrhoeae has developed resistance to nearly every antibiotic ever used to treat it, with ceftriaxone now standing as the only consistently effective first-line drug. Azithromycin resistance is widespread enough that the CDC removed it from empirical dual therapy for gonorrhea in 2020, and reduced cefixime susceptibility has been tracked in surveillance data for years.
The risk profile is not random. Travelers to regions with high resistance rates, including parts of Southeast Asia and the Western Pacific, return with strains that already carry multiple resistance markers. Sexual networks that overlap with those travelers see the same strains within weeks. People with frequent new partners and limited testing are the bridge population resistance loves most.
You do not need to be reckless to encounter a resistant strain. You only need a partner who encountered one, anywhere in the chain. That is the whole point of the WHO's continued push for global surveillance. Resistance crosses borders faster than treatment guidelines update.
The CDC places drug-resistant Neisseria gonorrhoeae in its "urgent" category of antibiotic-resistance threats, the highest priority tier. Operationally, that designation drives more frequent surveillance sampling, faster clinical alerts when treatment failures are reported, and active monitoring through the Gonococcal Isolate Surveillance Project and the WHO's GASP network.
Myth #2: "One pill of azithromycin still cures most STIs"
Azithromycin once carried real weight in STI treatment. A single 1 g oral dose was widely used for chlamydia and was paired with ceftriaxone for gonorrhea. That era is over.
The CDC STI Treatment Guidelines removed dual therapy with azithromycin for uncomplicated gonorrhea in 2020. Ceftriaxone monotherapy is now the recommended regimen. The change was driven by rising azithromycin resistance documented across the WHO's Gonococcal Antimicrobial Surveillance Programme.
For Mycoplasma genitalium, azithromycin monotherapy has cure rates that vary by country but often fall well below 50% in populations with established macrolide resistance. The CDC now recommends resistance-guided therapy: test for macrolide-resistance markers, choose azithromycin only if the strain is susceptible, and otherwise move to moxifloxacin or another agent.
For chlamydia, doxycycline 100 mg twice daily for 7 days has overtaken azithromycin as the preferred regimen because it produces higher cure rates, particularly for rectal infections.
The takeaway: a leftover Z-Pak is not the answer for any current STI suspicion. It risks partial clearance, which selects for the toughest survivors and leaves the patient still infectious. If a clinician offers a prescription, the right question is, "Is this drug active against my specific strain, including any resistance pattern in my region?"
| Infection | Preferred regimen (CDC) | Why azithromycin moved off front-line |
|---|---|---|
| Uncomplicated gonorrhea | Ceftriaxone 500 mg IM (single dose) | Rising azithromycin resistance led CDC to drop dual therapy in 2020 |
| Chlamydia (genital or rectal) | Doxycycline 100 mg twice daily for 7 days | Higher cure rates, especially for rectal infections, vs. single-dose azithromycin |
| Mycoplasma genitalium, macrolide-susceptible | Azithromycin 1-day load + 2.5 g over 4 days | Only used when resistance testing confirms susceptibility |
| Mycoplasma genitalium, macrolide-resistant | Moxifloxacin 400 mg daily for 7 days | Resistance markers are common; CDC recommends resistance-guided therapy |
| Syphilis (all stages) | Benzathine penicillin G (stage-dependent dosing) | Macrolide-resistant Treponema pallidum strains rule out azithromycin |
Myth #3: "Symptoms vanished, so I must be cured"
Gonorrhea symptoms can fade on their own as the immune system tamps down acute inflammation, especially in pharyngeal and rectal infections, which are often asymptomatic to begin with. Chlamydia is famously silent in most women and a large share of men. Mycoplasma genitalium causes symptoms in a minority of carriers. Feeling fine after a course of antibiotics is not, on its own, evidence that the bug is gone.
The CDC recommends a test-of-cure in specific situations: pharyngeal gonorrhea, suspected treatment failure, persistent symptoms, and pregnancy. The WHO supports the same approach. For Mycoplasma genitalium, the CDC explicitly recommends a test-of-cure 21 days after completing therapy because treatment failure is common enough to plan for rather than be surprised by.
The cost of skipping the follow-up is not theoretical. Untreated gonorrhea can ascend and cause pelvic inflammatory disease, with downstream consequences for fertility. Untreated chlamydia carries the same risk. From a public-health perspective, a person who thinks they are cured but is not stays in the sexual network, transmitting a strain that already proved resistant to the first-line drug. That is exactly how resistance moves through a community.
If you are treated, schedule the recommended follow-up test. If a clinic does not offer one for your specific infection, ask whether at-home rapid screening could close the gap for symptom rechecks between visits.
Myth #4: "Doxy-PEP makes condoms optional"
Doxycycline post-exposure prophylaxis (doxy-PEP) is real, evidence-based, and useful for the right people. A 200 mg dose of doxycycline taken within 72 hours of condomless sex meaningfully reduces the incidence of bacterial STIs in trial populations, particularly among men who have sex with men and transgender women with a recent STI history.
The CDC's clinical guidance recommends doxy-PEP for these specific groups, alongside continued condom use and quarterly STI screening, not as a replacement for either (CDC STI Treatment Guidelines). The recommendation is narrower than social-media chatter suggests. It is not a universal prophylaxis recommendation, and it is not effective against viral STIs at all. HIV transmission requires PrEP or condoms, and HSV and HPV are not affected by doxycycline.
Doxycycline's resistance footprint matters just as much as its prevention benefit. Doxycycline is a tetracycline, and widespread use exerts selection pressure on the very organisms it is supposed to suppress. Surveillance signals suggest rising tetracycline resistance in commensal Neisseria species, which can swap resistance genes with N. gonorrhoeae through horizontal gene transfer. Modeling studies project that broad community-level use of doxy-PEP could accelerate tetracycline resistance, although the trajectory depends heavily on uptake patterns and population.
The practical position: if you are in a CDC-recommended group, talk to a clinician about doxy-PEP and pair it with regular screening. If you are not in that group, condoms remain the highest-yield, lowest-cost prevention with no resistance footprint at all.
Current CDC clinical guidance restricts doxy-PEP eligibility to two groups: (1) men who have sex with men, and (2) transgender women, in each case with a bacterial STI diagnosis in the prior 12 months. Both groups are advised to take 200 mg doxycycline within 72 hours of condomless sex, continue condom use, and screen for STIs every 3 months so resistance trends are tracked alongside benefit.
Myth #5: "At-home tests can't help when resistance is the worry"
This one needs a two-part answer.
First part: a home rapid lateral-flow test, the kind sold on this site, tells you whether the infection is present. It does not tell you which antibiotic will work. Antimicrobial susceptibility testing requires either culture of the live organism or molecular testing for specific resistance markers, both of which happen in a laboratory, not on a cassette in a bathroom.
Second part: that limitation does not make at-home rapid tests irrelevant to the resistance picture. They serve three concrete functions that resistance-aware screening depends on:
- Frequency. Resistance management requires earlier detection. A home test you actually use every 1 to 3 months catches infections sooner than a clinic visit you keep postponing.
- Pre-clinic triage. A positive home result gives you a specific reason to book a clinic appointment that can include a swab culture for susceptibility testing. The home test does not replace that visit. It accelerates it.
- Symptom rechecks between recommended retests. If symptoms return after a full course of treatment, a home rapid test is one of the fastest ways to flag the need for a clinic visit, where culture-based confirmation and susceptibility testing can happen.
At-home rapid tests sit alongside clinic testing as a screening and triage layer, not in place of it. Resistance management is a team effort between home and lab.
An evidence-based testing playbook for 2026
An evidence-aligned testing plan for sexually active adults with new partners, drawn from the CDC STI Treatment Guidelines and parallel WHO guidance, breaks down across five situations:
| Situation | Frequency | Tests to include |
|---|---|---|
| Starting with a new partner | Baseline screen at the start | HIV, syphilis, chlamydia, and gonorrhea at all exposed anatomic sites |
| Multiple partners or in a CDC higher-frequency group | Every 3 to 6 months | Full panel at all exposed sites (genital, plus pharyngeal and rectal where relevant) |
| Symptoms appear | Promptly, whenever they appear | Targeted by symptom: discharge, sores, urinary symptoms, sore throat without a clear cold, unexplained pelvic pain |
| Treatment follow-up | Per CDC timing for the specific infection | Test-of-cure for pharyngeal gonorrhea, M. genitalium at 21 days, chlamydia in pregnancy, any suboptimal treatment |
| Oral or anal sex is part of the picture | Each routine screen | Add pharyngeal and rectal swabs; genital-only swabs miss many extragenital infections |
Resistance during pregnancy: a quieter, larger problem
Drug-resistant STIs in pregnancy carry consequences the rest of the resistance conversation often skips past. Congenital syphilis cases in the United States rose sharply through the 2010s and early 2020s. The CDC tracks the increase in detail and continues to publish updated case counts on its surveillance pages.
The mechanism is straightforward: an untreated or inadequately treated maternal infection crosses the placenta or transmits at delivery, with outcomes ranging from miscarriage and stillbirth to severe neonatal disease. Syphilis is the most discussed example, but untreated maternal gonorrhea, chlamydia, and HIV each carry their own neonatal risks.
The CDC's recommended prenatal screening pattern, summarized in the STI Treatment Guidelines, includes:
- HIV, syphilis, chlamydia, and hepatitis B at the first prenatal visit.
- Repeat syphilis screening in the third trimester for people in higher-prevalence areas or with risk factors.
- Repeat chlamydia testing in the third trimester for those under 25 or with new partners.
- Gonorrhea screening for those with risk factors, with retest in the third trimester if positive.
Resistance complicates this picture because some treatment options narrow during pregnancy. Doxycycline is generally avoided. Ceftriaxone remains usable, and penicillin remains the only proven therapy for syphilis in pregnancy, including in pregnant people with a penicillin allergy, who should be desensitized rather than substituted to a second-line drug.
If you are pregnant, a single early screen is not enough. Repeat testing through the third trimester is the standard, and it is worth asking about specifically.
Gonorrhea has progressively developed resistance to the antibiotic drugs prescribed to treat it. Ceftriaxone is the only remaining first-line treatment for gonorrhea in the United States.
The bottom line: keep curiosity, kill complacency
Antibiotic-resistant STIs reward complacency, not complexity. The myths above all share a common DNA. They oversimplify. They reduce a layered clinical picture to a one-line shortcut: take this pill, skip this test, trust this symptom, lean on this prophylaxis. Each shortcut creates exactly the conditions resistant strains depend on: partial treatment, undetected infection, and missed follow-up.
The five honest replacements are not complicated either:
- Assume resistance is possible. Plan testing accordingly.
- Do not use leftover antibiotics for a current concern.
- Symptom resolution is not cure. Schedule the recommended test-of-cure when it applies.
- Use doxy-PEP only inside CDC guidance, and pair it with screening and condoms.
- Use at-home rapid tests for frequency and triage, and use clinic testing for susceptibility-guided treatment.
The pathogen does not get a vote on which approach you take. It just adapts to whichever one you pick. The five myths above all let the pathogen win quietly. The five replacements above keep it on the back foot, which is exactly where you want it.
FAQs
- Are drug-resistant STIs more contagious than non-resistant strains?
- No. The transmission biology is identical. The difference is that resistant infections often stay untreated longer, which lengthens the period of contagiousness and widens the chance of onward transmission.
- Can I tell from symptoms whether I have a resistant infection?
- Not reliably. Persistent or returning symptoms after a complete course of treatment can be a flag, but many resistant infections look identical to non-resistant ones at first. The only way to confirm resistance is laboratory testing: culture-based susceptibility testing, or molecular detection of specific resistance markers.
- Do condoms still work against drug-resistant gonorrhea?
- Yes. Condoms work as a physical barrier and do not care about a strain's antibiotic susceptibility profile. The WHO and CDC continue to recommend condoms as a primary prevention tool for bacterial STIs regardless of regional resistance patterns.
- Will a typical at-home rapid STI test detect resistance?
- No, and the reason matters for how you use the result. Rapid lateral-flow chemistry targets the pathogen's antigens; it has no mechanism for probing the resistance genes that govern antibiotic susceptibility. Confirming resistance requires a lab swab culture or molecular resistance panel, both of which need a clinic visit. A positive home test is the trigger to book that visit, not the end of the process.
- Is antibiotic resistance permanent once I have a resistant infection?
- Resistance is a property of the bacterium, not of your body. Once the infection is cleared with an effective drug, the resistant organisms leave with the infection. You can be reinfected later by a resistant or a non-resistant strain.
- Should I stop antibiotics early if my symptoms resolve?
- No. Stopping early selects for the bacteria that survived the shortest exposure, which are the most resistant ones. Complete the full prescribed course and attend any recommended follow-up testing. The CDC and ECDC are consistent on this point.
- Does doxy-PEP create more antibiotic resistance?
- It can. Widespread use of doxycycline applies selection pressure on bacteria, and surveillance is tracking rising tetracycline resistance markers in some populations. Current CDC guidance restricts doxy-PEP to specific high-risk groups and pairs its use with quarterly STI testing, which is how the resistance question gets actively monitored rather than assumed away.
- How soon should I retest after STI treatment?
- It depends on the infection. CDC guidance recommends a test-of-cure 7 to 14 days after treatment for pharyngeal gonorrhea, 21 days for Mycoplasma genitalium, and routine retesting at 3 months for chlamydia and gonorrhea after a documented infection. Pregnant people often need retesting in the third trimester regardless of earlier results.
- U.S. Centers for Disease Control and Prevention. Drug-Resistant Gonorrhea clinical overview, including the history of resistance and current ceftriaxone-based first-line therapy.
- World Health Organization. Multi-drug-resistant gonorrhoea fact sheet, including global resistance trends and recommendations for surveillance and treatment.
- U.S. Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines, covering recommended regimens, test-of-cure recommendations, doxy-PEP guidance, and resistance-guided therapy for Mycoplasma genitalium.
- World Health Organization. Antimicrobial resistance fact sheet covering global drivers of resistance and implications for STI treatment.
- U.S. Centers for Disease Control and Prevention. Antimicrobial Resistance overview, including patient-level guidance on completing antibiotic courses and not reusing leftover prescriptions.
- U.S. Centers for Disease Control and Prevention. STI Surveillance, including national case counts for chlamydia, gonorrhea, syphilis, and congenital syphilis trends.
